European Market Highlights: High Leads 3 Promising Penny Stocks

Simply Wall St

Thu, Jul 17, 2025, 2:04 AM 4 min read

The European market has recently experienced a mixed performance, with the pan-European STOXX Europe 600 Index ending slightly higher amid hopes for more trade deals, although gains were curbed by tariff concerns. As investors navigate these shifting conditions, they often seek opportunities in various segments of the market. Penny stocks, though an outdated term, still represent a niche area where smaller or newer companies can offer growth potential when backed by strong financial health. This article will explore three promising penny stocks that may provide hidden value and long-term potential despite their modest price points.

Click here to see the full list of 332 stocks from our European Penny Stocks screener.

Let’s dive into some prime choices out of the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: High Co. SA offers consumer engagement chain solutions in France, Belgium, and Spain with a market cap of €85.29 million.

Operations: The company generates €146.38 million in revenue from its advertising segment.

Market Cap: €85.29M

High Co. SA, with a market cap of €85.29 million, generates €146.38 million in revenue from its advertising segment across France, Belgium, and Spain. The company maintains high-quality earnings without significant shareholder dilution over the past year and has reduced its debt to equity ratio to 0% over five years. Despite stable weekly volatility and well-covered interest payments by EBIT (57.2x), it faces challenges with negative earnings growth (-27.4%) last year and declining profit margins (5.3% from 7.3%). While trading below fair value estimates, future earnings are forecasted to decline by an average of 15.3% annually over three years.

• Get an in-depth perspective on High’s performance by reading our balance sheet health report here.

• Review our growth performance report to gain insights into High’s future.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Isofol Medical AB (publ) is a clinical stage biotech company with a market cap of SEK161.52 million.